Skip to main content
Ashkan Emadi, MD, Oncology, Morgantown, WV

AshkanEmadiMDPhD

Oncology • Morgantown, WV

Hematologic Oncology, Clinical Pharmacology

Professor of Medicine and Pharmacology at University of Maryland School of Medicine; Associate Director for Clinical Research Greenebaum Comprehensive Cancer Center; Director Translational Genomics Laboratory

Join to view full profile

Dr. Emadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Emadi's full profile

Already have an account?

  • Office

    1 Medical Center Dr
    Morgantown, WV 26506
    Phone+1 304-598-4500
    Fax+1 410-328-6896

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
  • University of Cincinnati Medical Center/College of Medicine
    University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2005 - 2007
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineInternship, Internal Medicine, 2004 - 2005
  • Illinois Institute of Technology
    Illinois Institute of TechnologyPhD, Organic Chemistry, 2000 - 2004
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 1999

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2006 - 2026
  • WV State Medical License
    WV State Medical License 2024 - 2026
  • OH State Medical License
    OH State Medical License 2005 - 2007
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Ashkan Emadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Groundbreaking Study Co-Authored by WVU Cancer Institute Physician Could Lead to Better Treatment for Acute Myeloid Leukemia
    Groundbreaking Study Co-Authored by WVU Cancer Institute Physician Could Lead to Better Treatment for Acute Myeloid LeukemiaNovember 19th, 2024
  • MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)
    MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
  • $50 Million Gift Will Spur Development of Morgantown Cancer Center
    $50 Million Gift Will Spur Development of Morgantown Cancer CenterApril 7th, 2024

Professional Memberships

Dr. Ashkan Emadi, Dr. Ashkan Emadi, MD, Dr. A Emadi